Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
Inhibiting TGF-β1 to increase immune responses against tumors bears the risk of tumor-promoting toxicity. Here the authors show that selectively blocking TGF-β1 produced by immunosuppressive cells is feasible with anti-GARP:TGF-β1 antibodies and improves the efficacy of PD-1 blockade immunotherapy....
Saved in:
Main Authors: | Grégoire de Streel, Charlotte Bertrand, Nicolas Chalon, Stéphanie Liénart, Orian Bricard, Sara Lecomte, Julien Devreux, Mélanie Gaignage, Gitte De Boeck, Lore Mariën, Inge Van De Walle, Bas van der Woning, Michael Saunders, Hans de Haard, Elien Vermeersch, Wim Maes, Hans Deckmyn, Pierre G. Coulie, Nicolas van Baren, Sophie Lucas |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/8a55d3ad04c940c5ae3df3fd9a81d1dc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
by: González-Cao M, et al.
Published: (2015) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
by: LAI Yanliang, et al.
Published: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2021)